The following drugs have been approved, conditionally approved, or granted emergency use authorization by the U.S. Food and Drug Administration (FDA) for the prevention and/or treatment of infestations caused by New World screwworm (NWS; Cochliomyia hominivorax) larvae (myiasis) in various animal species. See the FDA's website for more information.

Note that FDA requires that veterinarians prescribing drugs granted an emergency use authorization (EUA) inform clients that the products are lawfully authorized for emergency use, but are not fully FDA approved for the treatment or prevention of NWS myiasis. Veterinarians are responsible for discussing the potential risks and benefits of EUA drugs with clients, as well as any available alternatives. For food-producing animals, veterinarians also must inform clients of any applicable withdrawal times specified in a product's Letter of Authorization.

Veterinary facilities using or dispensing EUA products must maintain records that include client and patient information (name, age, disease manifestation); product information (number of doses administered or prescribed, lot number, and co-administered drugs); and the specific EUA condition for which the product is used. Refer to each product's Letter of Authorization for specific recordkeeping requirements. For more details, see the FDA’s letter to veterinarians.

Drugs that are conditionally approved or that have received an EUA are not available for extralabel use, unless they have a full FDA approval for another indication.

For more guidance on how a drug’s approval or authorization status affects veterinary prescribing, dispensing, and compliance requirements, visit avma.org/FDAapproval.

Read full details here: